A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancerRebecca Kristeleit, Udai Banerji, Ruth Plummer et al.|British Journal of Cancer|2023Cited by 36
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trialJames Spicer, Sophia N. Karagiannis, Gareth J. Veal et al.|Nature Communications|2023Cited by 35
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Farasat Kazmi et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8